H.C. Wainwright Sticks to Their Buy Rating for Verrica Pharmaceuticals (VRCA)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Verrica Pharmaceuticals (VRCA) with a $12.00 price target. This contrasts with the broader analyst consensus, which rates VRCA as a Moderate Buy with an average price target of $16.00.
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Verrica Pharmaceuticals today and set a price target of $12.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Urogen Pharma, and Rhythm Pharmaceuticals. According to TipRanks, Selvaraju has an average return of 21.3% and a 56.08% success rate on recommended stocks.
Currently, the analyst consensus on Verrica Pharmaceuticals is a Moderate Buy with an average price target of $16.00.